PMADS

Id:	acc5064
Group:	1sens
Protein:	PKCmiu
Gene Symbol:	PRKD1
Protein Id:	Q15139
Protein Name:	KPCD1_HUMAN
PTM:	phosphorylation
Site:	Ser744
Site Sequence:	GEKSFRRSVVGTPAYLAPEVL
Disease Category:	Immune system diseases
Disease:	Rheumatoid Arthritis
Disease Subtype:
Disease Cellline:
Disease Info:
Drug:	Bradykinin (BK)
Drug Info:	"Bradykinin (BK) is a nonapeptide involved in various physiological processes, including vasodilation, inflammation, and pain perception. It acts by binding to specific receptors and plays a crucial role in the regulation of blood pressure and tissue homeostasis."
Effect:	modulate
Effect Info:	"BK activates MAPKs (ERK1/2, p38 MAPK, JNK1/2) through PKCμ, leading to the phosphorylation of transcription factors AP-1 (c-Jun/c-Fos) and NF-kappaB, which in turn promotes the intensification of the inflammatory response and the progression of RA."
Note:	inducer
Score:	4.0
Pubmed(PMID):	28288820
Sentence Index:	28288820_0
Sentence:	Resveratrol inhibits BK-induced COX-2 transcription by suppressing acetylation of AP-1 and NF-kappaB in human rheumatoid arthritis synovial fibroblasts.

Sequence & Structure:

MSAPPVLRPPSPLLPVAAAAAAAAAALVPGSGPGPAPFLAPVAAPVGGISFHLQIGLSREPVLLLQDSSGDYSLAHVREMACSIVDQKFPECGFYGMYDKILLFRHDPTSENILQLVKAASDIQEGDLIEVVLSASATFEDFQIRPHALFVHSYRAPAFCDHCGEMLWGLVRQGLKCEGCGLNYHKRCAFKIPNNCSGVRRRRLSNVSLTGVSTIRTSSAELSTSAPDEPLLQKSPSESFIGREKRSNSQSYIGRPIHLDKILMSKVKVPHTFVIHSYTRPTVCQYCKKLLKGLFRQGLQCKDCRFNCHKRCAPKVPNNCLGEVTINGDLLSPGAESDVVMEEGSDDNDSERNSGLMDDMEEAMVQDAEMAMAECQNDSGEMQDPDPDHEDANRTISPSTSNNIPLMRVVQSVKHTKRKSSTVMKEGWMVHYTSKDTLRKRHYWRLDSKCITLFQNDTGSRYYKEIPLSEILSLEPVKTSALIPNGANPHCFEITTANVVYYVGENVVNPSSPSPNNSVLTSGVGADVARMWEIAIQHALMPVIPKGSSVGTGTNLHRDISVSISVSNCQIQENVDISTVYQIFPDEVLGSGQFGIVYGGKHRKTGRDVAIKIIDKLRFPTKQESQLRNEVAILQNLHHPGVVNLECMFETPERVFVVMEKLHGDMLEMILSSEKGRLPEHITKFLITQILVALRHLHFKNIVHCDLKPENVLLASADPFPQVKLCDFGFARIIGEKSFRRSVVGTPAYLAPEVLRNKGYNRSLDMWSVGVIIYVSLSGTFPFNEDEDIHDQIQNAAFMYPPNPWKEISHEAIDLINNLLQVKMRKRYSVDKTLSHPWLQDYQTWLDLRELECKIGERYITHESDDLRWEKYAGEQGLQYPTHLINPSASHSDTPETEETEMKALGERVSIL

No data.

Known Drugs:

source: Multi-Sources

(see table)

Target	Drug name	MOA	Phase	Status	Disease	Source
PRKD1	MIDOSTAURIN	Protein kinase C (PKC) inhibitor	4	-	acute myeloid leukemia	FDA
PRKD1	MIDOSTAURIN	Protein kinase C (PKC) inhibitor	4	-	neoplasm	ATC
PRKD1	MIDOSTAURIN	Protein kinase C (PKC) inhibitor	4	-	mast-cell leukemia	DailyMed FDA
PRKD1	MIDOSTAURIN	Protein kinase C (PKC) inhibitor	4	-	Mastocytosis	DailyMed
PRKD1	MIDOSTAURIN	Protein kinase C (PKC) inhibitor	4	-	systemic mastocytosis	FDA
PRKD1	MIDOSTAURIN	Protein kinase C (PKC) inhibitor	3	Recruiting	acute myeloid leukemia	ClinicalTrials ClinicalTrials
PRKD1	MIDOSTAURIN	Protein kinase C (PKC) inhibitor	3	Completed	acute myeloid leukemia	ClinicalTrials ClinicalTrials
PRKD1	MIDOSTAURIN	Protein kinase C (PKC) inhibitor	3	Unknown status	leukemia	ClinicalTrials
PRKD1	MIDOSTAURIN	Protein kinase C (PKC) inhibitor	2	Withdrawn	acute myeloid leukemia	ClinicalTrials ClinicalTrials
PRKD1	MIDOSTAURIN	Protein kinase C (PKC) inhibitor	2	Active, not recruiting	myelodysplastic syndrome	ClinicalTrials
PRKD1	MIDOSTAURIN	Protein kinase C (PKC) inhibitor	2	Recruiting	myelodysplastic syndrome	ClinicalTrials
PRKD1	MIDOSTAURIN	Protein kinase C (PKC) inhibitor	2	Active, not recruiting	acute myeloid leukemia	ClinicalTrials ClinicalTrials
PRKD1	MIDOSTAURIN	Protein kinase C (PKC) inhibitor	2	Completed	acute myeloid leukemia	ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials
PRKD1	MIDOSTAURIN	Protein kinase C (PKC) inhibitor	2	Recruiting	acute myeloid leukemia	ClinicalTrials ClinicalTrials
PRKD1	MIDOSTAURIN	Protein kinase C (PKC) inhibitor	2	Terminated	acute myeloid leukemia	ClinicalTrials
PRKD1	MIDOSTAURIN	Protein kinase C (PKC) inhibitor	2	Completed	leukemia	ClinicalTrials
PRKD1	UCN-01	Protein kinase C (PKC) inhibitor	2	Terminated	lymphoma	ClinicalTrials
PRKD1	SOTRASTAURIN	Protein kinase C (PKC) inhibitor	2	Completed	psoriasis	ClinicalTrials
PRKD1	SOTRASTAURIN	Protein kinase C (PKC) inhibitor	2	Completed	ulcerative colitis	ClinicalTrials
PRKD1	UCN-01	Protein kinase C (PKC) inhibitor	2	Completed	small cell lung carcinoma	ClinicalTrials
PRKD1	UCN-01	Protein kinase C (PKC) inhibitor	2	Terminated	melanoma	ClinicalTrials
PRKD1	UCN-01	Protein kinase C (PKC) inhibitor	2	Completed	pancreatic carcinoma	ClinicalTrials
PRKD1	MIDOSTAURIN	Protein kinase C (PKC) inhibitor	2	Completed	mast-cell leukemia	ClinicalTrials
PRKD1	MIDOSTAURIN	Protein kinase C (PKC) inhibitor	2	Recruiting	Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	ClinicalTrials
PRKD1	SOTRASTAURIN	Protein kinase C (PKC) inhibitor	2	Completed	panuveitis	ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets

Small molecule

Antibody

PROTAC

Other modalities

Approved Drug

Advanced Clinical

Phase 1 Clinical

Structure with Ligand

High-Quality Ligand

High-Quality Pocket

Med-Quality Pocket

Druggable Family

Approved Drug

Advanced Clinical

Phase 1 Clinical

UniProt loc high conf

GO CC high conf

UniProt loc med conf

UniProt SigP or TMHMM

GO CC med conf

Human Protein Atlas loc

Approved Drug

Advanced Clinical

Phase 1 Clinical

Literature

UniProt Ubiquitination

Database Ubiquitination

Half-life Data

Small Molecule Binder

Approved Drug

Advanced Clinical

Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

PRKD1-Ser205
Cancer	Intensity
BRCA	0.652
COAD	-0.409
HGSC	2.518
ccRCC	-0.075
GBM	-0.159
HNSC	0.152
LUAD	-0.339
LUSC	0.206
non_ccRCC	-0.289
PDAC	-1.465
UCEC	-0.792

PRKD1-Ser208
Cancer	Intensity
BRCA	0.466
COAD	-0.581
HGSC	2.255
ccRCC	-0.054
GBM	0.301
HNSC	-0.08
LUAD	-0.208
LUSC	0.133
non_ccRCC	0.457
PDAC	-1.777
UCEC	-0.911

PRKD1-Ser219
Cancer	Intensity
BRCA
COAD
HGSC	-0.707
ccRCC	0.707
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PRKD1-Ser233
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM	-0.063
HNSC
LUAD
LUSC
non_ccRCC	-0.967
PDAC
UCEC	1.03

PRKD1-Ser235
Cancer	Intensity
BRCA
COAD
HGSC	1.097
ccRCC
GBM
HNSC
LUAD	-0.235
LUSC
non_ccRCC
PDAC	-0.861
UCEC

PRKD1-Ser236
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	-0.131
GBM	0.264
HNSC
LUAD
LUSC	0.644
non_ccRCC	-1.653
PDAC
UCEC	0.876

PRKD1-Ser237
Cancer	Intensity
BRCA
COAD
HGSC	0.502
ccRCC
GBM
HNSC
LUAD	0.649
LUSC
non_ccRCC
PDAC	-1.152
UCEC

PRKD1-Ser243
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	-0.378
GBM	1.146
HNSC
LUAD
LUSC	0.191
non_ccRCC	-1.491
PDAC
UCEC	0.531

PRKD1-Ser245
Cancer	Intensity
BRCA	-0.926
COAD	0.42
HGSC
ccRCC	0.462
GBM
HNSC
LUAD
LUSC	1.195
non_ccRCC
PDAC
UCEC	-1.151

PRKD1-Ser249
Cancer	Intensity
BRCA
COAD
HGSC	1.47
ccRCC
GBM
HNSC	-0.341
LUAD	-0.356
LUSC
non_ccRCC
PDAC	-0.773
UCEC

PRKD1-Ser251
Cancer	Intensity
BRCA
COAD
HGSC	0.707
ccRCC
GBM
HNSC	-0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PRKD1-Ser257
Cancer	Intensity
BRCA	1.265
COAD	0.661
HGSC
ccRCC	-0.478
GBM	-1.22
HNSC
LUAD
LUSC	-0.638
non_ccRCC	-0.732
PDAC
UCEC	1.142

PRKD1-Ser259
Cancer	Intensity
BRCA
COAD	0.707
HGSC
ccRCC	-0.707
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PRKD1-Ser353
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM	-0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	0.707

PRKD1-Ser397
Cancer	Intensity
BRCA
COAD
HGSC	1.029
ccRCC
GBM
HNSC
LUAD	-0.062
LUSC
non_ccRCC
PDAC	-0.968
UCEC

PRKD1-Ser405
Cancer	Intensity
BRCA	-0.73
COAD	-0.048
HGSC
ccRCC	0.102
GBM	-0.114
HNSC
LUAD
LUSC	1.838
non_ccRCC	-1.394
PDAC
UCEC	0.346

PRKD1-Ser407
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	0.334
GBM	0.791
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	-1.124

PRKD1-Ser409
Cancer	Intensity
BRCA
COAD	0.334
HGSC
ccRCC
GBM	0.791
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	-1.124

PRKD1-Ser421
Cancer	Intensity
BRCA
COAD
HGSC	0.707
ccRCC
GBM
HNSC
LUAD	-0.707
LUSC
non_ccRCC
PDAC
UCEC

PRKD1-Ser429
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM	-0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	0.707

PRKD1-Ser481
Cancer	Intensity
BRCA
COAD	1.04
HGSC
ccRCC	0.288
GBM
HNSC
LUAD
LUSC	0.025
non_ccRCC	-1.354
PDAC
UCEC

PRKD1-Ser557
Cancer	Intensity
BRCA
COAD	0.707
HGSC
ccRCC
GBM	-0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PRKD1-Ser738
Cancer	Intensity
BRCA
COAD
HGSC	0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC	-0.707
UCEC

PRKD1-Ser742
Cancer	Intensity
BRCA
COAD
HGSC	0.234
ccRCC
GBM
HNSC	0.794
LUAD	0.431
LUSC
non_ccRCC
PDAC	-1.459
UCEC

PRKD1-Ser746
Cancer	Intensity
BRCA	1.263
COAD	-1.11
HGSC
ccRCC	-0.74
GBM	1.067
HNSC
LUAD
LUSC	-0.76
non_ccRCC	-0.52
PDAC
UCEC	0.8

PRKD1-Ser750
Cancer	Intensity
BRCA	1.616
COAD	-0.29
HGSC
ccRCC	-0.662
GBM	-0.127
HNSC
LUAD
LUSC	0.292
non_ccRCC	0.686
PDAC
UCEC	-1.515

PRKD1-Tyr260
Cancer	Intensity
BRCA
COAD	0.707
HGSC
ccRCC	-0.707
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links:

CTD
DMRdb